Journal list menu
Export Citations
ISSUE INFORMATION
CASE REPORT
Continuous alcohol withdrawal delirium and physical illness-associated delirium in a man brought to the emergency department after a disaster: A case report
- Pages: 486-489
- First Published: 25 April 2024

A 76-year-old heavy drinker with type 2 diabetes developed severe alcohol withdrawal delirium after being hospitalized for conditions caused by a typhoon, necessitating treatment with lorazepam and comprehensive care. This case highlights the importance of multidisciplinary treatment and long-term monitoring for elderly patients with alcohol dependence, particularly after disasters.
ORIGINAL ARTICLE
Evaluation of the effect of Modafinil in the improvement of the level of consciousness in patients with COVID-19 encephalopathy: A randomized controlled trial
- Pages: 490-501
- First Published: 08 May 2024
High prevalence of severe pain is associated with low opioid availability in patients with advanced cancer: Combined database study and nationwide questionnaire survey in Japan
- Pages: 502-511
- First Published: 12 May 2024
Cluster analysis of patients with alcohol use disorder featuring alexithymia, depression, and diverse drinking behavior
- Pages: 512-520
- First Published: 21 May 2024

This study aimed to investigate cluster analysis of alcohol use disorder (AUD) featuring alexithymia, depression, and diverse drinking behavior. Cluster analysis identified three subtypes, that is, Cluster 1 (core AUD type) predominant with pathological drinking behavior highlighting automaticity, Cluster 2 (late-onset type) manifested by relatively late-onset of alcohol use and less depressive symptoms or pathological drinking behavior, and Cluster 3 (alexithymic type) characterized by alexithymia, depression, and pathological drinking behavior more featuring coping with negative affect.
CASE REPORT
Long prodromal symptoms of neuroleptic malignant syndrome in patient with intellectual developmental disorder—A case report
- Pages: 521-525
- First Published: 04 June 2024

Neuroleptic malignant syndrome (NMS) is a rare and potentially life-threatening condition that may arise at any point during treatment and is often associated with adverse reactions to dopamine-blocking agents. This report presents a 38-year-old female with bipolar disorder and intellectual disability who has shown prodromal symptoms of NMS for several weeks.
ORIGINAL ARTICLE
A psychometric analysis of the Japanese version of the clinically useful depression outcome scale supplemented with questions for the DSM-5 anxious distress specifier (CUDOS-A)
- Pages: 526-533
- First Published: 05 June 2024

We conducted a study using the Japanese version of the CUDOS-A on 131 MDD outpatients and 200 healthy controls, demonstrating excellent reliability and validity. The instrument effectively differentiated between MDD patients and controls, proving valuable for assessing anxious distress alongside depression in Japan. Additionally, within the MDD group, it was observed that depressive symptoms were significantly more severe in the subgroup with anxious distress compared to those without anxious distress. Therefore, the identification of anxious distress in patients with depression holds clinical importance, and the CUDOS-A, capable of achieving this, shows potential for widespread clinical utility.
TECHNICAL NOTE
Development of the Japanese version of the Challenging Experience Questionnaire
- Pages: 534-539
- First Published: 18 June 2024
CASE REPORT
Neuropsychiatric manifestations due to anticholinergic agents and anabolic steroids ingestion: A case series and literature review
- Pages: 540-544
- First Published: 18 June 2024
Anticholinergic toxicity is a frequently encountered condition in the emergency room. Anticholinergic drugs, used as muscle relaxants, compete with acetylcholine at muscarinic receptors in the body. Neuropsychiatric effects of anticholinergic agents and anabolic steroids (ASs) can manifest as symptomsz like anxiety, agitation, dysarthria, hallucinations, bizarre behavior, and psychosis.
REVIEW ARTICLE
The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systematic review and meta-analysis
- Pages: 545-556
- First Published: 25 June 2024

Supplementation with n-3 PUFA shows potential in slowing cognitive decline in AD patients, as indicated by the CDR scale. However, our findings suggest no clear distinctions between various n-3 PUFA supplements. These results highlight both the potential benefits and limitations of dietary interventions in managing cognitive decline in AD patients.
ORIGINAL ARTICLE
Brexpiprazole: A new option in treating agitation in Alzheimer's dementia—Insights from transgenic mouse models
- Pages: 557-568
- First Published: 25 June 2024

Brexpiprazole was evaluated on agitation-related behaviors in two transgenic mouse models of Alzheimer's dementia. Brexpiprazole suppressed attack behavior and reduced nocturnal hyperlocomotion in these model mice, which may be indicative of the therapeutic effect of brexpiprazole on agitation in Alzheimer's dementia, as demonstrated in the clinical trials.
CASE REPORT
Major depressive disorder after heart transplantation with partial response to antidepressant therapy and remission with aripiprazole augmentation: A case report
- Pages: 569-571
- First Published: 25 June 2024

A woman diagnosed with major depressive disorder (MDD) following a heart transplant experienced partial improvement with antidepressant treatment but continued to suffer from loss of appetite. Augmentation treatment with aripiprazole improved her appetite, and her MDD went into remission. When antidepressant treatment alone is not sufficiently effective for post-heart transplantation MDD, augmentation treatment with antipsychotics, such as aripiprazole, should be considered.
REVIEW ARTICLE
Neurophysiological profiles of patients with bipolar disorders as probed with transcranial magnetic stimulation: A systematic review
- Pages: 572-584
- First Published: 26 June 2024

This systematic review examined the neurophysiological profiles of patients with bipolar disorder (BD) using transcranial magnetic stimulation. The review found that patients with BD had consistently reduced short-interval cortical inhibition compared to healthy controls (HCs), suggesting gamma-aminobutyric acid (GABA)-A receptor-mediated neurophysiological function may be impaired. In addition, decreased long-interval intracortical inhibition and cortical silent period were observed in patients with BD compared to HC, suggesting GABA-B receptor-mediated neurophysiological impairment. These results indicate that impaired GABAergic neurophysiological function may underlie the important pathophysiological basis of the disorder in patients with BD.
CASE REPORT
Successful treatment with guanfacine in a long-COVID case manifesting marked cognitive impairment
- Pages: 585-590
- First Published: 27 June 2024
ORIGINAL ARTICLE
Effect of prior depression diagnosis on bipolar disorder outcomes: A retrospective cohort study using a medical claims database
- Pages: 591-598
- First Published: 02 July 2024

This study explored the effects of a prior major depressive disorder (MDD) diagnosis on outcomes in patients diagnosed with bipolar disorder. Neither a history of MDD diagnosis nor the length of diagnosed duration significantly predicted the changes in rates of psychiatric hospitalization post-diagnosis of bipolar disorder. Instead, a history of MDD diagnosis was associated with reduced hospitalization rates for all causes, and a diagnosis of MDD for more than a year showed decreased mortality rates.
CASE REPORT
Successful utilization of clozapine for a patient with treatment-resistant schizophrenia after recurrent violent behavior
- Pages: 599-603
- First Published: 03 July 2024

We report a case of treatment-resistant schizophrenia that exhibited recurrent violent behavior. Utilization of clozapine resulted in the cessation of his aggressive behavior by adjusting dosing schedule based on the therapeutic drug monitoring. This case underscores clozapine's efficacy in managing aggression, highlighting the importance of therapeutic drug monitoring.
ORIGINAL ARTICLE
Constipation-associated factors in outpatients with schizophrenia: A multicenter questionnaire survey
- Pages: 604-613
- First Published: 03 July 2024

Individuals with schizophrenia often suffer from constipation, which could be a result of the illness itself or the side effects of psychotropic medications. We conducted a survey using self-administered questionnaires and medical records to identify factors associated with constipation in psychiatric outpatients. The analysis suggested that female gender, the doses of antiparkinsonian medications, and benzodiazepine sleeping pills may be associated with constipation.
MICRO REPORT
Effect of concomitant use of yokukansan on steady-state blood concentrations of donepezil and risperidone in real-world clinical practice
- Pages: 614-619
- First Published: 08 July 2024

This exploratory study investigated whether yokukansan affects steady-state blood concentrations of donepezil and risperidone, mainly metabolized by CYP2D6 and/or CYP3A, and the major metabolites of both drugs in a real-world clinical setting. The plasma concentrations of donepezil and its primary metabolites M1, M2, M6, risperidone, its metabolite paliperidone, and the active moiety (i.e., risperidone + paliperidone) did not differ before and after the 8-week treatment with yokukansan. The findings of this study showed that the effect of yokukansan on steady-state plasma concentrations of donepezil and risperidone, as well as their metabolites, was small compared with the large individual variability in their blood concentrations.
ORIGINAL ARTICLE
Obesity-associated factors in psychiatric outpatients: A multicenter questionnaire survey
- Pages: 620-630
- First Published: 15 July 2024
Comprehensive analysis including in-game spending and violent game playing in patients with internet gaming disorder
- Pages: 631-638
- First Published: 28 July 2024
REVIEW ARTICLE
Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective
- Pages: 639-649
- First Published: 29 July 2024

Findings from different studies highlighted the neuroprotective role uric acid against the development and progression of AD and PD. The neuroprotective effect of uric acid is mediated by mitigating oxidative stress-induced neurodegeneration. Long-term effect of hyperuricemia predisposes for the development and progression of cognitive impairment by inducing oxidative stress, release of pro-inflammatory TNF-α and accumulation of Aβ.
ORIGINAL ARTICLE
Effect of A118G (rs1799971) single-nucleotide polymorphism of the μ-opioid receptor OPRM1 gene on intraoperative remifentanil requirements in Japanese women undergoing laparoscopic gynecological surgery
- Pages: 650-657
- First Published: 02 August 2024
Photopharmacological modulation of hippocampal local field potential by caged-glutamate with MicroLED probe
- Pages: 658-662
- First Published: 09 August 2024

Photopharmacology is a new technique for modulating biological phenomena through the photoconversion of substances in a specific target region at precise times, and, here, we investigated whether a microscale light-emitting diode (MicroLED) probe is applicable for the photoconversion of caged-glutamate (caged-Glu) in vivo. In the caged-Glu-injected hippocampal dentate gyrus, the local field potential changed in the 10–20 Hz frequency ranges after light illumination, whereas there was no change in the ACSF control condition. These results indicate that the MicroLED probe is applicable for photopharmacological experiments and treatments.
Correlation between myelin basic protein levels in cerebrospinal fluid and motor speed in patients with schizophrenia
- Pages: 663-670
- First Published: 12 August 2024